5 documents

Read All
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

AVX-470 regulatory update

FDA granted Orphan Drug designation to AVX-470 from Avaxia to treat pediatric ulcerative colitis (UC). The oral inhibitor of tumor necrosis factor (TNF) alpha completed a Phase Ib trial in adults with UC (see BioCentury,...
Read More
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

AVX-470: Phase Ib data

A double-blind, placebo-controlled, international Phase Ib trial in 36 patients with active UC showed that once-daily 0.2, 1.6 and 3.5 g doses of oral AVX-470 for 28 days were well tolerated with no treatment-related serious...
Read More
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

AVX-470: Phase Ib started

Avaxia began a double-blind, placebo-controlled, international Phase Ib trial to evaluate 0.2, 1.6 and 3.5 g oral AVX-470 daily for 28 days in about 24 patients with active UC. Avaxia Biologics Inc. , Lexington, Mass....
Read More
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Avaxia Biologics, Courtagen Life Sciences deal

The companies partnered to develop an assay to evaluate the effect of Avaxia's AVX-470 in treating gastrointestinal damage following radiation exposure in preclinical models and in humans. The companies will use Courtagen's Avantra Q400 Protein...
Read More
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

Avaxia Biologics other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Avaxia a two-year, $2.9 million contract for preclinical testing of AVX-470 to treat gastrointestinal injury caused by radiation exposure when given 24 hours after exposure. The...
Read More